Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Kura Oncology, Inc.
Servier
Daiichi Sankyo
Astellas Pharma Inc
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Lumos Pharma
OHSU Knight Cancer Institute
PETHEMA Foundation
M.D. Anderson Cancer Center
Stanford University
Massachusetts General Hospital
Emory University
Stanford University
National Cancer Institute (NCI)
Roswell Park Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Kentucky
Massachusetts General Hospital
Fred Hutchinson Cancer Center